Symbiotec Pharmalab Ltd
- Market cap
- ₹ 7,518 Cr.
- P/E
- 71x
- P/B
- 6.69x
- 52-week range
- 934.2 – 1,309.9
- ROE
- 12%
- ROCE
- 13%
- Dividend yield
- 0%
- Debt / equity
- 0.34
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Symbiotec Pharmalab Limited is an India-based research and development-driven, science-based pharmaceutical and biotechnology company. The Company operates through three platforms: organic chemistry, biotechnology and complex injectables. It manufactures its products using fermentation and multi-step complex chemical reactions. It has two operational industrial scale active pharmaceutical ingredients (API) manufacturing facilities: Rau, Mhow, Indore (Rau Facility) and Pithampur Special Economic Zone, Madhya Pradesh (SEZ Facility). It has a product portfolio of over 60 corticosteroid and steroidal-hormone APIs that are supplied globally, including Hydrocortisones, Betamethasones, Methylprednisolones, Progesterones, Estrogens and Testosterones. Its Rau Facility- Streoid products include Beclomethasone Dipropionate USP (Micronized & Non-Micronized), Betamethasone Dipropionate, Betamethasone Valerate, USP (Micronized), Clobetasol Propionate USP, Deflazacort Micronized and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Symbiotec Pharmalab Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)71 against a typical 34.3: pricier than most peers (1st = cheapest).176th of 220
- Size₹ 7,517.7 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).45th of 199
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 21 Sep 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Sales | 203 | 245 | 218 |
| Expenses | 145 | 183 | 173 |
| Operating Profit | 58 | 62 | 45 |
| OPM % | 29% | 25% | 21% |
| Other Income | 3 | 0 | 0 |
| Interest | 5 | 7 | 6 |
| Depreciation | 11 | 20 | 22 |
| Profit before tax | 45 | 35 | 18 |
| Tax % | 33% | 22% | 20% |
| Net Profit | 30 | 28 | 14 |
| EPS in Rs | 46.99 | 4.39 | 2.24 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 7%
- 3 Years
- 15%
- TTM
- 16%
- 10 Years
- —
- 5 Years
- −1%
- 3 Years
- 70%
- TTM
- 19%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 12%
- 3 Years
- 13%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Symbiotec Pharmalab Ltd | ₹ 1,270.10 | ₹ 7,518 Cr. | 71x | 6.7x | 12% | — |
| Kinetic Trust | ₹ 48.51 | ₹ 16 Cr. | — | — | — | — |
Management
- Raghav Khandelwal
- Chief Financial Officer
- Raghavender Ramachandran
- Chief Financial Officer
- Salil Jain
- Company Secretary
- S. Ranganath
- Company Secretary
- Anil Kumar Satwani
- Managing Director (Promoter)
Prices are delayed and for information only. Nothing on this page is investment advice.